ESC/EAS 2019 guidelines state that apoB analysis is recommended as secondary lipid analysis for risk evaluation, especially for patients who have high TG levels, diabetes mellitus, obesity, metabolic syndrome or very low LDL-C levels [22]. This evidence concerns the gene APOB and metabolic syndrome.